Search results
Preterm Birth and Maternal Cardiovascular Risk
Author(s):
Jorge Segovia-Reyes
,
Andrea Iboleon-Jimenez
,
María Jiménez-Salva
,
et al
Added:
1 week ago
Review Article
Narendra Singh
Job title: Adjunct Clinical Assistant Professor
Author
Yutao Guo
Research Area(s) / Expertise:
Author
Author(s):
Harriette Van Spall
,
Mark Petrie
Added:
1 year ago
HFA 2024 — Join experts, Dr Harriette Van Spall (McMaster University, CA) and Dr Mark Petrie (University of Glasgow, UK) for an insightful wrap up of the novel data presented at 2024's Heart Failure Congress.00:24 - STEP HFpEF Programme: Semaglutide 2.4 mg and NTproBNP in obesity-related HFpEF & Semaglutide therapy and diuretic use in obesity-related HFpEF02:20 - EMPACT-MI: The effect of…
View more
Isabelle C Van Gelder
Research Area(s) / Expertise:
Job title: Professor of Cardiology
Author
John Rawlins
Job title: Consultant Interventional Cardiologist
Author
Roxy Senior
Research Area(s) / Expertise:
Author
Added:
3 months ago
Source:
Radcliffe Cardiology
A new study has revealed significant delays in the diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) following an initial diagnosis of heart failure (HF), with the median time to diagnosis exceeding one year.¹ Timely identification of ATTR-CM is critical to reduce morbidity and mortality, as effective treatments are available.²MethodologyThis retrospective cohort study analysed data…
View more
Added:
1 month ago
Source:
Radcliffe CVRM
Recent US guidelines have controversially recommended lowering the low-density lipoprotein cholesterol (LDL-C) target to <55 mg/dL for patients with established atherosclerotic cardiovascular disease (ASCVD).¹˒² The Ez-PAVE trial is the first randomised study to directly compare this intensive target with a conventional target of <70 mg/dL. The findings were published in The New England…
View more